Stability and Stabilization Studies of TAK-599 (Ceftaroline Fosamil), a Novel N-Phosphono Type Prodrug of Anti-methicillin Resistant Staphylococcus aureus Cephalosporin T-91825
TAK-599 (known as ceftaroline fosamil) is a novel N-phosphono type prodrug of a cephalosporin compound, T-91825, that exhibits strong activity against methicillin resistant Staphylococcus aureus (MRSA). The stability and stabilization of TAK-599 were investigated by kinetic analysis focused on cryst...
Saved in:
Published in: | Chemical & Pharmaceutical Bulletin Vol. 56; no. 10; pp. 1406 - 1411 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | Japanese |
Published: |
Pharmaceutical Society of Japan
2008
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | TAK-599 (known as ceftaroline fosamil) is a novel N-phosphono type prodrug of a cephalosporin compound, T-91825, that exhibits strong activity against methicillin resistant Staphylococcus aureus (MRSA). The stability and stabilization of TAK-599 were investigated by kinetic analysis focused on crystallinity and moisture content. Initially it was planned to develop TAK-599 as an injectable formulation using the amorphous solid powder prepared by lyophilization. However, amorphous of TAK-599 free form was found to be chemically unstable even when stored at 8℃, and thus development was focused on the crystalline material. After exhaustive screening of crystallization condition, the monoacetic acid solvate was found to yield TAK-599 in a crystalline form. Physicochemical properties were studied to identify the key factors affecting the stabilization of TAK-599 in order to improve long-term stability, and the results indicated that the crystallinity of TAK-599 correlated with stability. Furthermore, moisture content was also identified in our studies as an important factor in stabilizing TAK-599. TAK-599 containing about 3% moisture was found to be the most stable form. It was concluded that both sufficient crystallinity and strict moisture control of TAK-599 were essential to maintain long-term stability at 25℃. |
---|---|
AbstractList | TAK-599 (known as ceftaroline fosamil) is a novel N-phosphono type prodrug of a cephalosporin compound, T-91825, that exhibits strong activity against methicillin resistant Staphylococcus aureus (MRSA). The stability and stabilization of TAK-599 were investigated by kinetic analysis focused on crystallinity and moisture content. Initially it was planned to develop TAK-599 as an injectable formulation using the amorphous solid powder prepared by lyophilization. However, amorphous of TAK-599 free form was found to be chemically unstable even when stored at 8℃, and thus development was focused on the crystalline material. After exhaustive screening of crystallization condition, the monoacetic acid solvate was found to yield TAK-599 in a crystalline form. Physicochemical properties were studied to identify the key factors affecting the stabilization of TAK-599 in order to improve long-term stability, and the results indicated that the crystallinity of TAK-599 correlated with stability. Furthermore, moisture content was also identified in our studies as an important factor in stabilizing TAK-599. TAK-599 containing about 3% moisture was found to be the most stable form. It was concluded that both sufficient crystallinity and strict moisture control of TAK-599 were essential to maintain long-term stability at 25℃. |
Author | Junko BANa Yukihiro IKEDAa Hidetoshi HORIBEa Tomoyasu ISHIKAWAa Shohei HASHIGUCHIa Shinichi URAYAMAb |
Author_xml | – sequence: 1 fullname: Yukihiro IKEDAa – sequence: 2 fullname: Junko BANa – sequence: 3 fullname: Tomoyasu ISHIKAWAa – sequence: 4 fullname: Shohei HASHIGUCHIa – sequence: 5 fullname: Shinichi URAYAMAb – sequence: 6 fullname: Hidetoshi HORIBEa |
BookMark | eNotUNFKwzAU7cME59w_5FHBQNK0SfM4hlNxzKH1uWRJaiNpUppUmF_lJ5rpXu7hwL3nnHuuspnzTs-yOUKIw5xQcpktQzAHlBNcUl4V8-znLYqDsSYegXAKnNm3iMa7xCZldAC-BfXqGZacg5u1bqMYvTVOg40Pojf29g4IsPNf2oId3Hc-DJ13HtTHQYP96NU4fZwkVi4a2OvYGWlsugevOpgQhYsn26E7Wi-9lFMAYhp1grUeOmGTnB_Tdg05rvLyOrtohQ16ecZF9r65r9ePcPvy8LRebWGPSV5BRjhiuSRKFxyVlCquWIkkqgjmhOJSK8YVlQUTTKkDVpSnSjjjLUcaY0nJItv86_ZaGZliuNPLzaefRpd8GxmY7HRvmhyhqkHJA6MEtMHF38A4J4ymzn8BIuJ3TA |
ContentType | Journal Article |
CorporateAuthor | bPharmaceutical Production Division Takeda Pharmaceutical Company Ltd aPharmaceutical Research Division Takeda Pharmaceutical Company Ltd |
CorporateAuthor_xml | – name: aPharmaceutical Research Division Takeda Pharmaceutical Company Ltd – name: bPharmaceutical Production Division Takeda Pharmaceutical Company Ltd |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EndPage | 1411 |
ExternalDocumentID | cs7chemi_2008_005610_006_1406_1411237636 |
GroupedDBID | --- .55 .GJ 29B 2WC 3O- 53G 5GY 6J9 ABTAH ACGFO ACIWK ACPRK ADBBV AENEX AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 L7B MOJWN OK1 P2P RJT RZJ TKC TR2 VH1 X7J X7M XSB ZE2 ZGI ZY4 |
ID | FETCH-LOGICAL-m1328-739072c3de490566d9d750c083193615ed79d6c47a7ddb1d69315979f90e11c63 |
ISSN | 0009-2363 |
IngestDate | Fri Nov 08 06:52:50 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-m1328-739072c3de490566d9d750c083193615ed79d6c47a7ddb1d69315979f90e11c63 |
PageCount | 6 |
ParticipantIDs | medicalonline_journals_cs7chemi_2008_005610_006_1406_1411237636 |
PublicationCentury | 2000 |
PublicationDate | 20080000 |
PublicationDateYYYYMMDD | 2008-01-01 |
PublicationDate_xml | – year: 2008 text: 20080000 |
PublicationDecade | 2000 |
PublicationTitle | Chemical & Pharmaceutical Bulletin |
PublicationYear | 2008 |
Publisher | Pharmaceutical Society of Japan |
Publisher_xml | – name: Pharmaceutical Society of Japan |
SSID | ssib023156984 ssib014648066 ssj0025073 ssib002822113 ssib017383858 |
Score | 1.9143877 |
Snippet | TAK-599 (known as ceftaroline fosamil) is a novel N-phosphono type prodrug of a cephalosporin compound, T-91825, that exhibits strong activity against... |
SourceID | medicalonline |
SourceType | Publisher |
StartPage | 1406 |
Title | Stability and Stabilization Studies of TAK-599 (Ceftaroline Fosamil), a Novel N-Phosphono Type Prodrug of Anti-methicillin Resistant Staphylococcus aureus Cephalosporin T-91825 |
URI | http://mol.medicalonline.jp/en/journal/download?GoodsID=cs7chemi/2008/005610/006&name=1406-1411e |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9owELZYnzZN035qXbvJD1u1KVgiJCTx05RROigSQmqq7Q0F21FYSzwRMon_an_i7hITkj51mvZAAJMY8H06313uviPk_RJ7N4gkZrD5JMy1VZ_xpS1YopSdeAG4PjHWDo-v_Nn34HzkjjqdPQ_xYey_ShrGQNZYOfsX0q4nhQF4DTKHI0gdjveSO1iPZb5rxatk3lW1lvukQTQQo3DKBpyXN3FVsq2a9yjrQucY8fjQ52VapzXTv9StNWPzVOeYxa4tdFyxvEBuijJdOsy2K4Z9qFcCQzflDQG0SbMtfjkIEXZLLUSRW3GxUfA0VD_T-FajOw1nR6AHg6oouSZM2HMYICrnaSvm3mILL_uJ3azS1UZbk-noPKy3mMsiu9HWl3BWj0R6rXdxXlgYoJuG3w7nXqU6VStrHMIHX6-H40ncioQENWrv_JR9viuswSVYHFlL_3PWd4xKNfq_Ijbf47zX0ObgfHoNy8B2zb7QJugWuS9wYUxHT3TJkHLVW-DlC7wIM48cpIV3QaWi4T6ZNl1e8MFrHQkblxs0GPZt3wmafENgjg88jrXFJqgA9nzdLRD_2SPyeF3d4quoVhrWUvSUPDFuDg0rfD4jnR_xc3JmVnDXpdGh7C_v0jM6PzCo716Q3zWIKYCYtkBMDYipTqgBMf3YgDA1EP7UpTEt4Usb8KUIX2rgi1PchS-t4Uvb8KUVfGkLvtTA9yW5vhhFwzEzrUXY2nb6AfMd3vP7wpHK5SAwT3IJprPAtnvcASNfSZ9LT7h-7Eu5tKXHYd25zxPeU7YtPOcVOcp0pl4TKnhSksaBJSxdX7qBdHkyiGN4yIFwnGPyuSWQhVEW-eK-wHnzzzOckIdVnhOGDk_J0XZTqLfkQS6LdyUa_wAa_crJ |
link.rule.ids | 315,782,786,4030 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stability+and+Stabilization+Studies+of+TAK-599+%28Ceftaroline+Fosamil%29%2C+a+Novel+N-Phosphono+Type+Prodrug+of+Anti-methicillin+Resistant+Staphylococcus+aureus+Cephalosporin+T-91825&rft.jtitle=Chemical+%26+Pharmaceutical+Bulletin&rft.au=Yukihiro+IKEDAa&rft.au=Junko+BANa&rft.au=Tomoyasu+ISHIKAWAa&rft.au=Shohei+HASHIGUCHIa&rft.date=2008&rft.pub=Pharmaceutical+Society+of+Japan&rft.issn=0009-2363&rft.volume=56&rft.issue=10&rft.spage=1406&rft.epage=1411&rft.externalDocID=cs7chemi_2008_005610_006_1406_1411237636 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-2363&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-2363&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-2363&client=summon |